- Home
- GNPX vs SNSE Comparison
GNPX vs SNSE Comparison
Compare GNPX & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- SNSE
- Stock Information
- Founded
- GNPX 2009
- SNSE 2005
- Country
- GNPX United States
- SNSE United States
- Employees
- GNPX N/A
- SNSE N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- GNPX Health Care
- SNSE Health Care
- Exchange
- GNPX Nasdaq
- SNSE Nasdaq
- Market Cap
- GNPX 10.8M
- SNSE 10.3M
- IPO Year
- GNPX 2018
- SNSE 2021
- Fundamental
- Price
- GNPX $2.97
- SNSE $8.60
- Analyst Decision
- GNPX
- SNSE Strong Buy
- Analyst Count
- GNPX 0
- SNSE 5
- Target Price
- GNPX N/A
- SNSE $72.50
- AVG Volume (30 Days)
- GNPX 299.4K
- SNSE 39.5K
- Earning Date
- GNPX 11-14-2025
- SNSE 11-14-2025
- Dividend Yield
- GNPX N/A
- SNSE N/A
- EPS Growth
- GNPX N/A
- SNSE N/A
- EPS
- GNPX N/A
- SNSE N/A
- Revenue
- GNPX N/A
- SNSE N/A
- Revenue This Year
- GNPX N/A
- SNSE N/A
- Revenue Next Year
- GNPX N/A
- SNSE N/A
- P/E Ratio
- GNPX N/A
- SNSE N/A
- Revenue Growth
- GNPX N/A
- SNSE N/A
- 52 Week Low
- GNPX $2.77
- SNSE $5.00
- 52 Week High
- GNPX $63.00
- SNSE $18.35
- Technical
- Relative Strength Index (RSI)
- GNPX 42.93
- SNSE 44.73
- Support Level
- GNPX $2.77
- SNSE $8.37
- Resistance Level
- GNPX $5.00
- SNSE $9.42
- Average True Range (ATR)
- GNPX 0.48
- SNSE 1.08
- MACD
- GNPX -0.27
- SNSE -0.02
- Stochastic Oscillator
- GNPX 8.07
- SNSE 33.45
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).